On May 9, 2016, a disclosure statement with respect to a plan of reorganization or liquidation was filed in the bankruptcy case of KaloBios Pharmaceuticals, Inc. and its affiliates.
The filing was assigned docket number 435 and is described on the court’s official docket as follows:
Disclosure Statement With Respect To The Second Amended Plan Of Reorganization Of Kalobios Pharmaceuticals, Inc. Under Chapter 11 Of The Bankruptcy Code (related document(s)) Filed by Kalobios Pharmaceuticals, Inc. (Attachments: # (1) Exhibit A (The Plan) # (2) Exhibit B (The Stalking Horse SPA with Schedule 2.1) # (3) Exhibit C (The PIPE Settlement) # (4) Exhibit D (Liquidation Analysis)) (McLaughlin, Marcy)
KaloBios Pharmaceuticals, Inc. filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on December 29, 2015. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Delaware. The case number for the lead bankruptcy case is 15-12628. The bankruptcy case is currently assigned to United States Bankruptcy Judge Laurie Selber Silverstein. The law firm of Morris, Nichols, Arsht & Tunnell LLP is acting as lead bankruptcy counsel to KaloBios Pharmaceuticals, Inc. in the bankruptcy case.